Asitri Dashboard

Search Clinical Trials

The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.

Saved Searches

Choose Search
Basic Search
Targeted Search

Clinical Trials Search Results

Search History:
Count: 85
Selected: 0
NCT IDTitle
NCT03075826A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms
NCT04061421Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes Overlap Syndromes (ABNL-MARRO)
NCT03019003Oral Decitabine (ASTX727) and Durvalumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
NCT04857645ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients
NCT01357395A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer
NCT00005872Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
NCT00005873Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
NCT00881166Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors
NCT00032773Dose-finding Study Using Pentostatin for Injection in the Treatment of Steroid-refractory aGvHD
NCT05456269A Study of Bisantrene Combined With Cytarabine or With Decitabine for Adult Subjects With Extramedullary AML and MDS
NCT00005869Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
NCT04411030A Study to Investigate the Effect of CYP3A4 Inhibition on the Single Dose Pharmacokinetics of ASTX660 and the Effect of a Single Dose of ASTX660 on the Pharmacokinetics of the CYP3A4 Substrate Midazolam
NCT00043381Decitabine Versus Supportive Care in Adults With Advanced-stage MDS
NCT00005877Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
NCT03576963Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
NCT01696032SGI-110 in Combination With Carboplatin in Ovarian Cancer
NCT00496873Evaluation of the Safety and Efficacy of Nipent, Cytoxan, and Rituxan
NCT05245682Tolinapant and Radiation for Cisplatin-Ineligible, Previously Untreated, Locally Advanced Head and Neck Cancer
NCT03603964Guadecitabine Extension Study
NCT04466514A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029
NCT04637009A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms
NCT00254163Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patients
NCT02901899Guadecitabine and Pembrolizumab in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
NCT04479800Effect of Food on the Pharmacokinetics of ASTX660 in Healthy Volunteers
NCT04013880ASTX727 and FT-2102 in Treating IDH1-Mutated Recurrent/Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia
NCT05360160A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)
NCT00131313Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
NCT01183949Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma
NCT01685268A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate
NCT06802146Early Intervention in High Risk CCUS
NCT05835011A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)
NCT04134884Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
NCT00005874Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
NCT04250246A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1
NCT04155580A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia (AML)
NCT00042003Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT00006047Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
NCT04655755Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT03922555ASTX727 in Recurrent/Progressive Non-enhancing IDH Mutant Gliomas
NCT03813186Effect of Food on Blood Levels of ASTX727
NCT03306264Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML
NCT00144430Pentostatin for High Risk and Refractory Chronic Graft Versus Host Disease in Children
NCT00504205MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
NCT00041990Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)
NCT03875287Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
NCT00005876Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
NCT01652144A Phase II Study of AT7519M, a CDK Inhibitor, in Patients With Relapsed Mantle Cell Lymphoma
NCT00113113Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
NCT01294202A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
NCT00894894Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies